Affiliation:
1. From the Center for Metabolism and Endocrinology, Department of Medicine, and the Center for Nutrition and Toxicology, Novum, Karolinska Institute at Huddinge University Hospital, Huddinge (M.E., B.A.); King Gustaf V Research Institute, Karolinska Hospital, Stockholm (L.A.C.); and the Department of Medicine, University of Helsinki (T.A.M.).
Abstract
Background
—Apolipoprotein (apo) A-I is the major protein component of HDL, a cholesterol transport particle that protects against atherosclerosis. Apo A-I is believed to promote reverse cholesterol transport, transferring cholesterol from peripheral cells to the liver for subsequent elimination. To test this hypothesis in humans, we measured fecal steroid excretion before and after the intravenous infusion of human proapo A-I (precursor of apo A-I) liposome complexes.
Methods and Results
—Four subjects with heterozygous familial hypercholesterolemia were studied under standardized conditions. The fecal excretion of bile acids and neutral sterols was determined for 9 days before and 9 days after an intravenous infusion of recombinant human proapo A-I (4 g protein) liposome complexes. Plasma apoA-I and HDL cholesterol levels increased transiently (mean peak concentrations were 64% and 35% above baseline, respectively) during the first 24 hours. Mean lipoprotein lipid and apolipoprotein levels were not different during the 2 collecting periods, however. Serum lathosterol, a precursor of cholesterol whose concentration reflects the rate of cholesterol synthesis in vivo, was also unchanged. The fecal excretion of cholesterol (neutral sterols and bile acids) increased in all subjects (mean increase, +39% and +30%, respectively), corresponding to the removal of ≈500 mg/d excess cholesterol after infusion. Control infusions with only liposomes in 2 of the patients did not influence lipoprotein pattern or cholesterol excretion.
Conclusions
—Infusion of proapoA-I liposomes in humans promotes net cholesterol excretion from the body, implying a stimulation of reverse cholesterol transport. This mechanism may prove useful in the treatment of atherosclerosis.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Reference46 articles.
1. Breslow J. Familial disorders of high-density lipoprotein metabolism. In: Scriver CR Beaudet AL Sly WS Valle D eds. The Metabolic and Molecular Bases of Inherited Disease . 8th ed. New York NY: McGraw-Hill; 1995:2031–2052.
2. Grundy SM. Lipids nutrition and coronary disease. In: Fuster V Ross R Topol E eds. Atherosclerosis and Coronary Artery Disease . Philadelphia Pa: Lippincott-Raven; 1996:45–68.
3. Goldstein JL Hobbs HH Brown MS. Familial hypercholesterolemia. In: Scriver CR Beaudet AL Sly WS Valle D eds. The Metabolic and Molecular Bases of Inherited Disease . 8th ed. New York NY: McGraw-Hill; 1996:1981–2030.
4. Beyond Cholesterol
5. High density lipoprotein metabolism.
Cited by
212 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献